lactoferrin
lf
conserv
ironbind
mammalian
glycoprotein
antimicrobi
activ
present
secret
recov
mucos
site
regard
portal
entri
andor
invas
pathogen
agent
antimicrobi
activ
mostli
character
lf
bovin
human
origin
isol
milk
mechan
underli
antimicrobi
action
lf
result
direct
microbiostat
andor
microbicid
indirect
immunomodulatori
effect
present
therapeut
prophylact
treatment
microbi
infect
amelior
antibiot
multiresist
inflammatori
respons
prompt
search
agent
display
antimicrobi
modulatori
properti
lf
review
focus
modulatori
impact
lf
inflammatori
respons
induc
infecti
microorgan
mainli
gastrointestin
respiratori
tract
studi
modulatori
properti
lf
inflammatori
respons
impact
biotechnolog
develop
nanoparticl
lf
formul
potenti
clinic
implic
lf
isol
almost
time
human
hlf
bovin
blf
milk
glycoprotein
monomer
approxim
molecular
weight
kda
highli
cation
pi
tertiari
structur
figur
lf
consist
two
main
n
c
lobe
organ
domain
lobe
link
domain
threeturn
cleft
lie
domain
bind
one
ferric
ion
kd
total
lf
bind
two
ferric
ion
deriv
diet
ironload
transferrin
holotf
one
associ
synergist
bound
carbon
ion
two
domain
lobe
fulli
close
bound
metal
ion
lf
initi
name
lactotransferrin
due
milk
glycoprotein
chelat
iron
protein
belong
transferrin
famili
includ
avian
egg
ovotransferrin
ovotf
mammalian
serum
lymph
transferrin
tf
differ
member
famili
higher
affin
iron
lf
synthes
mammari
gland
abund
colostrum
milk
suggest
particip
initi
protect
newborn
regard
content
human
matur
milk
highli
enrich
lf
mgml
comparison
bovin
milk
mgml
amino
acid
sequenc
protein
exhibit
approxim
ident
lf
also
present
mani
fluid
exocrin
secret
tear
saliva
mucos
surfac
respiratori
urinaryreproduct
intestin
tract
site
lf
contribut
primari
innateimmun
defens
system
mammal
exert
antimicrobi
activ
extens
varieti
pathogen
lf
also
synthes
natur
cellular
develop
promyelocyt
myelocyt
earli
recogn
import
compon
secondari
granul
polymorphonuclear
pmn
neutrophil
cell
store
lf
neutrophil
releas
site
infect
acid
due
activ
pathogen
plasma
lf
deriv
neutrophil
concentr
low
nevertheless
patient
sepsi
degranul
activ
neutrophil
lead
secret
signific
level
lf
mgml
bloodstream
neutrophil
also
releas
lf
fece
whose
concentr
markedli
increas
inflammatori
process
inflammatori
bowel
diseas
ibd
ulcer
coliti
crohn
diseas
due
respons
pathogen
bacteria
physiolog
lf
found
fulli
ironload
hololf
ironfre
protein
apolf
hololf
conform
rigid
resist
denatur
proteolysi
apolf
instead
apolf
gener
effect
bacteria
hololf
regard
report
hololf
util
iron
sourc
sever
group
microorgan
howev
alway
case
studi
intestin
epithelialbarri
function
mucos
inflamm
carri
cell
model
macrophag
activ
lipopolysaccharid
lp
show
lf
form
effect
inhibit
proinflammatori
respons
nevertheless
apolf
effect
downregul
inflamm
probabl
due
abil
bind
neutral
lp
well
neutral
microbialderiv
antigen
therebi
potenti
reduc
proinflammatori
effect
much
evid
exist
success
experiment
use
lf
differ
origin
human
bovin
porcin
caprin
camelid
buffalo
growth
divers
pathogen
mention
result
indic
lf
differ
origin
exert
bacteriostat
effect
due
ironchel
activ
also
bactericid
due
interact
lp
porin
gramneg
bacteria
teichoic
acid
gramposit
bacteria
interact
lead
membran
damag
bacteri
death
moreov
antimicrobi
activ
lf
also
highli
depend
cation
properti
addit
posit
charg
lf
via
amid
enhanc
antibacteri
antivir
properti
contrast
addit
neg
charg
acyl
abolish
mention
lf
display
antivir
properti
common
viru
infect
antivir
properti
relat
abil
block
cellular
attach
replic
viru
induc
type
interferon
antivir
action
thu
lf
divers
mammal
show
potent
activ
replic
human
immunodefici
viru
cytomegaloviru
hepat
c
viru
less
inform
exist
microbicid
action
lf
fungi
protozoa
import
find
lf
synerg
antibiot
drug
even
protein
innat
immun
system
lysozym
natur
secretori
iga
siga
antibodi
potenti
antimicrobi
effect
largest
extern
sourc
lf
milk
consumpt
consum
lf
enzymat
cleav
pepsin
stomach
trypsin
small
intestin
adult
wherea
hlf
complet
degrad
blf
resist
proteolyt
digest
mediat
pepsin
noteworthi
mention
digest
tract
babi
infant
rel
high
ph
secret
low
level
pepsin
allow
innocu
transit
hlf
blf
epitheli
cell
extrem
import
stage
life
nevertheless
nativ
hlf
deriv
pancreat
juic
neutrophil
discharg
exocrin
secret
mucos
surfac
adult
thu
act
protect
site
invad
addit
divers
biolog
activ
lf
includ
facilit
iron
absorpt
modul
mucos
immun
stimul
mucos
differenti
result
interact
lf
receptor
lfr
express
gastrointestin
cell
one
reason
lf
use
pharmaceut
activ
maintain
compon
peptid
cleav
proteolyt
enzym
eg
peptid
deriv
terminu
lf
pepsin
socal
lactoferricin
lfcin
lack
ironchel
activ
character
strong
cation
charg
remark
lfcin
often
show
higher
microbicid
activ
parent
lf
well
synergist
act
drug
antibiot
microb
moreov
sever
lfcin
synthes
experi
microb
hand
synthet
lactoferrampin
fusion
peptid
call
lfchimera
success
assay
multiresist
bacteria
also
bacteria
typic
form
biofilm
synthet
lfchimera
also
shown
effect
parasit
protozoa
anoth
synthet
lfchimera
prepar
fusion
effect
pseudomona
aeruginosa
downregul
pyocyanin
elastas
biofilm
format
presenc
lf
secret
variou
mechan
action
allow
glycoprotein
combat
type
microb
colon
mucosa
differ
bodili
region
howev
depend
site
microb
expos
differ
concentr
lf
complex
lf
protein
divers
level
lf
deriv
time
lf
help
inflammatori
process
produc
strong
immun
reaction
infect
therefor
find
lf
activ
suggest
lf
lfcin
potenti
use
antimicrobi
antiinflammatori
compound
either
alon
adjunct
convent
antibiot
drug
sens
lf
one
studi
protein
sinc
commerci
point
view
highli
appreci
nutraceut
countri
promot
supplement
diarrheic
diseas
cancer
increas
immun
improv
memori
sever
condit
human
lf
clone
differ
vector
express
recombin
rhlf
overal
eukaryot
system
glycosyl
yeast
fungi
howev
best
product
obtain
transgen
cow
plant
interestingli
rhlf
express
cow
mammari
gland
enhanc
systemat
intestin
immun
respons
piglet
use
model
infant
addit
meat
progeni
hlf
transgen
cow
analyz
abnorm
nutrient
composit
found
thu
wide
use
lf
human
health
care
promissori
next
review
effect
lf
antiinflammatori
protein
number
infecti
diseas
studi
mainli
gastrointestin
respiratori
tract
throughout
gastrointestin
tract
lf
present
ironbind
multifunct
glycoprotein
regard
natur
compound
abl
inhibit
pathogen
growth
lf
also
abl
downmodul
humor
cellular
compon
immun
involv
regul
inflammatori
respons
key
role
maintain
gut
homeostasi
balanc
homeostasi
result
tight
regul
sever
event
sinc
littl
inflamm
disrupt
process
tissu
repair
remodel
wherea
much
inflamm
entail
collater
impact
caus
tissu
damag
lifethreaten
consequ
mucos
compart
small
intestin
scenario
take
place
physiolog
inflammatori
respons
orchestr
innat
adapt
mechan
mediat
intestin
epitheli
cell
wide
array
immunocompet
cell
lamina
propria
dendrit
cell
macrophag
lymphocyt
key
role
maintain
gut
homeostasi
combat
infect
howev
infecti
clinic
condit
larg
intestin
ibd
inflamm
doubleedg
sword
role
either
enabl
inhibit
cancer
develop
progress
comment
antimicrobi
activ
blf
wide
array
pathogen
profus
evidenc
contrast
data
regulatori
role
blf
paramet
gut
inflamm
caus
enteropathogen
microorgan
provid
limit
number
articl
find
vitro
vivo
model
infect
show
blf
display
downmodulatori
effect
proinflammatori
cytokin
profil
role
blf
resolut
infect
modul
mediat
inflamm
document
model
infect
caus
sever
strain
enteropathogen
bacteria
parasit
addit
found
lf
promot
develop
bifidobacterium
one
major
genera
bacteria
colon
flora
use
probiot
manner
independ
iron
satur
level
lf
effect
believ
help
maintain
gut
homeostasi
regard
gastric
inflamm
treatment
blf
hlf
singl
agent
combin
antimicrobi
drug
found
favor
erad
bacteria
protect
gastriti
caus
helicobact
pylori
helicobact
feli
describ
murin
model
howev
human
murin
trial
support
find
even
bacteri
growth
gastric
inflamm
seem
enhanc
blf
hlf
administr
controversi
data
may
reflect
experiment
clinic
set
lf
treatment
interestingli
lf
singl
compon
fail
erad
h
pylori
infect
combin
tripl
esomeprazol
clarithromycin
amoxicillin
therapi
probiot
favor
resolut
infect
amelior
inflammatori
respons
effect
combin
twoantibiot
treatment
describ
experiment
mice
treat
rhlf
transgen
goat
also
trail
patient
treat
nativ
blf
interestingli
rhlf
inhibit
growth
h
pylori
also
suppress
express
two
major
virul
factor
hand
sever
studi
demonstr
effect
lf
modul
inflamm
small
intestin
exampl
antiinflammatori
activ
rhlf
nativ
blf
test
model
bacteri
infect
shigella
flexneri
rabbit
salmonella
enterica
serovar
typhimurium
suscept
balbc
mice
unlik
lfuntreat
anim
macroscop
microscop
observ
evidenc
lf
treatment
favor
resolut
infect
protect
mice
tissu
damag
caus
intestin
inflamm
mechan
account
antiinflammatori
role
blf
may
result
part
elicit
siga
respons
key
role
lumin
clearanc
pathogen
downmodul
intestin
inflamm
although
lf
may
modul
inflamm
inhibit
growth
pathogen
iron
chelat
abil
apolf
ironfre
form
lf
use
studi
assay
base
murin
typhoid
model
show
pharmaceut
formul
ironsatur
blf
holoblf
enclos
nanocapsul
display
antimicrobi
activ
modulatori
properti
inflamm
latter
evidenc
downmodul
cytokin
involv
innat
adapt
immun
respons
well
hematopoiet
cytokin
key
role
gener
granulocyt
pmn
neutrophil
agranulocyt
monocytesmacrophag
phagocyt
thu
ironload
blf
nanocapsul
seem
evok
converg
innat
adapt
immun
respons
pro
antiinflammatori
cytokin
result
protect
toward
typhoid
infect
concomit
intestin
inflamm
downmodulatori
effect
blf
proinflammatori
cytokin
also
document
cultur
monolay
cell
infect
recombin
escherichia
coli
invas
strain
harbor
inv
gene
yersinia
pesti
strain
abl
accomplish
invas
intracellular
multipl
within
epitheli
cell
model
apoblf
well
holoblf
decreas
level
elicit
noninvas
e
coli
wild
type
strain
e
coli
invas
addit
apo
holoblf
inhibit
increas
respons
caus
e
coli
invas
strain
level
cytokin
remain
elev
find
suggest
effect
blf
toward
inflammatori
mediat
ironindepend
constant
high
level
provid
protect
induc
recruit
phagocyt
combat
infect
larg
intestin
regulatori
impact
blf
toward
inflammatori
respons
describ
vitro
model
infect
adher
invas
e
coli
aiec
strain
presum
role
pathogenesi
crohn
diseas
diseas
along
ulcer
coliti
two
clinic
entiti
ibd
character
abnorm
respons
commens
bacteria
colon
intestin
lumen
aiec
strain
found
lesion
inflam
colon
tissu
children
suffer
crohn
diseas
preponder
proinflammatori
respons
find
model
infect
aiec
indic
blf
inhibit
bacteri
invas
proinflammatori
cytokin
respons
epitheli
monolay
cultur
colon
biopsi
patient
crohn
diseas
suggest
potenti
therapeut
role
blf
antibacteri
antiinflammatori
agent
upmodulatori
effect
blf
inflammatori
cytokin
respons
bacteri
infect
found
assay
infect
aiec
monolay
stimul
mimic
preponder
respons
associ
cytokin
found
crohn
diseas
patient
data
assay
show
unstimul
infect
cell
blf
inhibit
bacteri
invas
surviv
infect
cell
prime
blf
increas
product
wherea
counteract
inhibitori
effect
aiec
infect
ferroportin
protein
express
ferroportin
iron
export
protein
regul
inflamm
determin
surviv
intracellular
pathogen
reduc
intracellular
iron
level
appar
conflict
data
describ
infect
model
aiec
strain
regard
antiinflammatori
versu
proinflammatori
role
blf
seem
evid
two
side
coin
ie
abil
blf
downmodul
inflammatori
respons
iron
avail
result
resolut
infect
parasit
infect
larg
intestin
previous
develop
model
intracec
infect
protozoan
entamoeba
histolytica
suscept
mice
strain
spontan
mutat
tlr
gene
simul
intestin
infect
caus
parasit
human
model
oral
therapeut
administr
blf
resolv
intestin
infect
amoeba
high
effici
effect
shown
associ
increas
local
express
elicit
siga
cecum
happen
salmonella
infect
interleukin
involv
upregul
siga
also
secondari
inflammatori
cytokin
exhibit
pro
antiinflammatori
properti
thu
oral
blf
administr
led
antiinflammatori
respons
mediat
cytokin
iga
collabor
protect
parasit
mainten
homeostasi
protect
impact
tissu
integr
hand
experiment
assay
conduct
mice
infect
enteroviru
blf
treatment
display
protect
action
result
hamper
viral
interact
host
cell
howev
vitro
assay
indic
blf
exhibit
suppress
activ
rotaviru
addit
assess
rotaviru
infect
incid
children
either
treat
blf
show
blf
neither
prevent
viral
infect
effect
level
marker
pro
antiinflammatori
interleukin
respect
thu
therapeut
action
blf
viral
enter
unclear
howev
assay
suckl
rat
show
administr
whey
protein
concentr
contain
blf
well
bioactiv
compon
favor
resolut
acut
gastroenter
caus
rotaviru
infect
result
suggest
synerg
effect
bulk
rather
singl
bioactiv
compon
provid
protect
enteroviru
sepsi
lifethreaten
syndrom
result
harm
effect
inflammatori
respons
associ
gut
system
infect
case
infecti
intestin
diseas
assess
inflammatori
paramet
regul
blf
respons
system
infect
analyz
limit
number
infect
model
induc
e
coli
strain
administ
enter
parenter
rout
case
model
mimic
sepsi
condit
found
human
system
infect
invas
enteropathogen
bacteria
immunocompet
host
microbiota
member
caus
opportunist
nosocomi
infect
neonat
adult
patient
underw
sole
parenter
nutrit
postsurgeri
antibiot
treatment
immunosuppress
among
condit
therapeut
action
blf
synthet
peptid
lfchimera
test
balbc
mice
infect
intragastr
rout
enterohemorrhag
e
coli
ehec
latter
food
born
pathogen
caus
mild
diarrhea
hemorrhag
coliti
patient
hemolyt
urem
syndrom
character
anemia
thrombocytopenia
kidney
injuri
infect
mice
underw
lf
lfchimera
treatment
fecal
bacteri
output
kidney
colon
found
reduc
lfchimera
significantli
decreas
mortal
rate
histolog
analysi
stain
tissu
slice
assess
inflammatori
respons
revel
lf
lfchimera
treatment
decreas
kidney
damag
comparison
mice
without
blf
treatment
show
tubular
necrosi
glomerular
injuri
intratubular
hyalin
cast
furthermor
vivo
vitro
assay
document
role
rhlf
gutrel
system
infect
e
coli
strain
caus
mening
orogastr
infect
neonat
rat
model
mimic
clinic
observ
neonat
evid
parenter
feed
sole
rout
nutrit
risk
factor
sepsi
result
transloc
microbiota
member
eg
gramneg
enterobacteria
intestin
tract
system
organ
via
bloodstream
potenti
fatal
consequ
treatment
rhlf
decreas
clinic
sepsi
ill
bacteri
load
kidney
blood
vitro
assay
macrophag
cultur
show
level
nitric
oxid
express
elicit
lp
even
higher
follow
addit
rhlf
find
suggest
protect
action
rhlf
result
optim
activ
macrophag
via
proinflammatori
cytokin
elicit
enhanc
bacteri
kill
activ
effect
blf
sepsi
caus
e
coli
staphylococcu
aureu
demonstr
cyclophosphamid
immunosuppress
mice
model
mimic
immunosuppress
therapi
autoimmun
neoplast
diseas
antisepsi
action
blf
evidenc
reduct
bacteri
load
spleen
liver
associ
rise
circul
leukocyt
induc
elicit
spleen
well
periton
macrophag
immunosuppress
mice
treat
blf
studi
mice
system
infect
e
coli
evidenc
blf
enhanc
kill
activ
recruit
neutrophil
action
blf
e
coli
sepsi
result
elicit
involv
product
acut
phase
protein
well
amelior
level
increas
respons
infect
sinc
high
level
circul
proinflammatori
cytokin
lethal
consequ
result
describ
suggest
abil
blf
control
increas
may
underli
protect
action
sepsi
found
vitro
vivo
assay
clinic
trial
confirm
potenti
applic
blf
prevent
nosocomi
sepsi
necrot
enterocol
prematur
neonat
diseas
associ
upmodul
regulatori
cell
involv
control
intestin
immun
respons
pathogen
strengthen
essenti
role
blf
control
intestin
homeostasi
pro
antiinflammatori
properti
lf
bacteri
infect
ascrib
abil
act
lpsbind
protein
lbp
modulatori
effect
either
hlf
blf
includ
deriv
lfcin
paramet
associ
inflamm
evidenc
model
intestin
systemicrel
endotoxemia
induc
lp
also
known
endotoxin
gramneg
enterobacteria
experiment
model
intend
assess
impact
lf
intestin
system
level
inflammatori
marker
elicit
lp
affect
gut
barrier
bacteri
transloc
diarrhea
tissu
damag
endotox
shock
among
other
case
experiment
assay
lp
administr
encompass
use
zymosan
dgalactosamin
dgaln
carrageenan
increas
sensibl
anim
toward
toxic
effect
low
lp
dose
porcin
lf
plf
bioactiv
deriv
plf
peptid
prove
confer
protect
mice
lp
damag
colon
associ
downmodulatori
action
proinflammatori
cytokin
elicit
express
tight
junction
protein
involv
regul
intestin
permeabl
ie
zonula
occludin
well
decreas
colon
apoptosi
protect
action
hlf
gut
barrier
function
lpsinduc
intestin
damag
also
describ
hlf
vitro
cultur
cell
jejun
segment
mice
underw
lpsendotoxemia
iron
statu
blf
impact
paramet
gut
barrier
function
document
cell
cultur
incub
murin
macrophag
howev
apoblf
display
stronger
neutral
effect
holoblf
proinflammatori
cytokin
gener
respons
lp
thermal
inactiv
e
coli
antigen
suggest
iron
content
may
determin
protect
role
lf
toward
inflamm
caus
gut
endotoxemia
andor
sepsi
intestin
level
neutral
activ
blf
hlf
test
model
endotoxemia
mice
induc
intraperiton
administr
lp
model
lp
neutral
blf
includ
enterogen
endotoxemia
rat
inject
carrageenan
intraperiton
rout
also
infect
e
coli
rat
treat
nebacetin
intraduoden
via
enabl
lp
releas
model
mice
endotoxemia
intraperiton
administr
hlf
provid
protect
deleteri
effect
lp
intestin
integr
moreov
blf
administ
intraperiton
rout
mice
attenu
lpsinduc
diarrhea
decreas
product
proinflammatori
mediat
power
diarrheagen
activ
ie
prostaglandin
e
pge
enterocyt
small
intestin
nitric
oxid
plasma
enterogen
endotoxemia
model
rat
blf
decreas
endotox
activ
lp
measur
plasma
dosedepend
manner
also
decreas
bacteri
load
mesenter
lymph
node
experiment
assay
neonat
mice
indic
feed
blf
andor
bifidobacteria
decreas
intestin
level
lp
without
chang
cell
popul
produc
peyer
patch
system
level
neutral
activ
hlfderiv
peptid
test
model
endotoxemia
mice
induc
intraven
administr
lp
dgaln
assay
exhibit
protect
activ
lethal
intraven
lp
challeng
decreas
circul
level
dual
action
lf
circul
seem
underli
protect
role
sinc
downmodul
provid
protect
deleteri
impact
endotoxemia
wherea
modulatori
role
lf
control
elicit
critic
erad
gutrel
system
infect
anoth
exampl
blf
display
prophylact
action
lethal
shock
occur
upon
intraven
inject
lp
germfre
piglet
valuabl
model
studi
primari
toxic
endotoxin
portion
lp
ie
lipid
rather
secondari
toxic
r
polysaccharid
portion
cultur
monocyt
lpstreat
piglet
blf
inhibit
interact
lp
antigen
surfac
marker
express
mononuclear
phagocyt
prime
phagocyt
cell
lp
via
ligat
result
elicit
power
proinflammatori
cytokin
includ
lethal
outcom
host
endotoxem
condit
moreov
oral
administr
blf
prior
intraven
lp
challeng
piglet
provid
protect
mortal
caus
lpsinduc
hypothermia
like
blf
protect
activ
hypothermia
describ
hlf
mice
underw
lpsendotoxemia
effect
blf
lpsneutral
e
coli
bacteremia
explor
lp
toxic
suscept
mice
carri
defect
gene
well
cba
mice
resist
lp
unlik
protect
activ
cba
mice
blf
fail
confer
protect
endotoxemia
e
coli
bacteremia
mice
due
inabl
amelior
elicit
prevent
decreas
thu
unbalanc
cytokin
respons
may
respons
high
suscept
lp
endotoxemia
mice
differenti
impact
concurr
prophylact
therapeut
effect
intraperiton
administr
hlf
endotoxemia
analyz
mice
intraven
administr
lp
concurr
scheme
hlf
administ
prior
lp
challeng
decreas
serum
level
nitric
oxid
prophylact
therapeut
protocol
hlf
significantli
downmodul
serum
nitric
oxid
signific
fluctuat
seen
level
mice
model
hepat
induc
intraperiton
coadministr
lp
zymosan
oral
administ
blf
decreas
serum
aspart
aminotransferas
activ
marker
liver
inflamm
increas
small
intestin
product
antiinflammatori
cytokin
role
amelior
inflammatori
respons
find
indic
upmodul
level
blf
seem
provid
therapeut
action
small
intestin
induc
lpszymosan
model
hepat
treatment
rhlf
also
analyz
mice
model
induc
hepat
experiment
scenario
rhlf
provid
protect
hepat
develop
determin
decreas
alanin
transaminas
activ
marker
liver
damag
associ
downmodul
serum
level
moreov
protect
effect
rhlf
found
mice
pretreat
gadolinium
chlorid
destroy
kupffer
cell
suggest
cell
sourc
target
rhlf
mechan
lf
action
inflammatori
respons
analyz
regard
abil
lf
interact
lp
block
interact
vitro
cultur
intestin
cell
line
murin
periton
cell
line
macrophag
assay
evidenc
lf
upmodul
lpsmediat
inflammatori
respons
via
depend
independ
signal
pathway
downmodulatori
impact
lpsmediat
inflamm
found
assay
intestin
porcin
epitheli
cell
line
treat
plfderiv
peptid
effect
result
abil
inhibit
signal
pathway
similarli
human
monocyt
cell
line
mono
mac
hlf
also
display
downmodulatori
activ
lpsassoci
cytokin
respons
block
bind
promot
assay
cultur
human
peripher
blood
mononuclear
cell
show
blf
display
antiinflammatori
respons
drive
differenti
lpstreat
monocyt
toward
dendrit
cell
low
capac
differenti
elicit
respons
counteract
mediat
activ
signal
hand
upmodulatori
impact
lf
inflammatori
effect
lp
document
assay
raw
macrophag
cell
line
periton
macrophag
indic
blf
form
complex
lp
enhanc
cytokin
respons
via
signal
pathway
howev
anoth
studi
suggest
upmodulatori
effect
lf
lpsmediat
inflamm
may
involv
pathway
signal
thu
assay
raw
macrophag
cell
line
treat
lp
show
elicit
level
blf
therefor
lf
display
dual
role
lpsmediat
respons
proinflammatori
cytokin
encompass
altern
rout
signal
presum
mechan
lpsmediat
inflamm
includ
abil
lf
control
express
ironregul
protein
found
monocytemacrophag
cultur
cell
lf
prevent
lpsinduc
decreas
ferroportin
reduc
level
mention
ferroportin
iron
bind
protein
involv
control
iron
level
inflammatori
respons
summari
find
describ
provid
experiment
evid
support
protect
role
lf
deleteri
effect
lpsinduc
proinflammatori
cytokin
respons
gutbarri
function
diarrhea
bacteri
transloc
tissu
damag
mind
antimicrobi
lpsbind
protein
activ
lf
applic
either
alon
combin
probiot
adjunct
compound
antibiot
may
repres
promis
strategi
treatment
prevent
sepsi
endotox
shock
human
respiratori
tract
rt
respons
mobil
million
liter
gase
throughout
life
deliveri
liferequir
oxygen
system
circul
organ
impli
potenti
incorpor
countless
particl
toxic
microb
counter
local
innat
adapt
immun
respons
avoid
entri
lung
tissu
circul
protect
lung
structur
function
infect
rt
frequent
popul
repres
consider
caus
worldwid
morbid
mortal
infect
upper
rt
common
cold
laryng
pharyng
epiglott
otiti
sinus
typic
caus
viru
bacteria
less
extens
fungi
exampl
common
cold
viral
diseas
consid
frequent
infect
human
caus
rhinovirus
coronaviru
parainfluenza
adenoviru
less
frequent
respiratori
syncyti
viru
enteroviru
howev
influenza
viru
common
caus
season
flu
simultan
affect
part
rt
includ
lower
tract
infect
lower
rt
mainli
caus
bacteria
also
viru
fungi
even
parasit
includ
bronchiti
pneumonia
pulmonari
abscess
among
other
tuberculosi
caus
bacterium
mycobacterium
tuberculosi
among
preval
infect
lower
rt
caus
mainli
pneumonia
also
affect
organ
rt
infect
accompani
inflammatori
process
whose
intens
depend
mani
variabl
includ
type
pathogen
virul
inoculum
affect
tissu
host
immunolog
statu
whether
infect
acut
chronic
although
inflammatori
process
essenti
control
invas
infecti
agent
develop
exacerb
chronic
inflamm
result
alter
respiratori
capac
due
lung
tissu
damag
includ
edema
increas
airway
resist
mucu
product
infect
influenza
viru
understand
inflamm
alter
respiratori
system
indispens
develop
better
therapeut
intervent
support
breath
lung
plastic
clinic
treatment
regard
evid
modul
rt
inflamm
blf
associ
certain
microb
report
use
sever
vitro
vivo
model
moreov
lf
consid
second
import
antimicrobi
antiinflammatori
peptid
lysozym
upper
rt
tuberculosi
far
studi
vivo
model
microbi
pulmonari
infect
bacteri
infect
affect
nearli
third
world
popul
rate
new
infect
approxim
per
year
target
bacillu
calmetteguerin
bcg
vaccin
wide
use
vaccin
world
remain
almost
unchang
sinc
studi
carri
show
singl
subcutan
immun
mice
mix
bcg
blf
emulsifi
freund
adjuv
follow
challeng
tuberculosi
aerosol
result
decreas
mycobacteri
load
lung
spleen
splenocyt
prolif
respons
heatkil
bcg
show
increas
product
subsequ
studi
group
show
blf
admix
bcg
vaccin
incomplet
freund
adjuv
pb
increas
mice
protect
tuberculosi
challeng
compar
mice
receiv
bcg
alon
addit
signific
reduct
lung
bacteri
load
associ
increas
product
splenocyt
mention
studi
blf
addit
vaccin
also
result
clear
reduct
lung
patholog
concomit
downregul
proinflammatori
mediat
suggest
main
action
lf
enhanc
bcg
vaccin
reli
immunomodulatori
properti
reduc
immunerel
tissu
patholog
part
modul
macrophag
dendrit
cell
abil
present
antigen
stimul
tcell
noteworthi
lymphocyt
recal
respons
toward
bcg
antigen
two
month
infect
higher
mice
receiv
lf
adjuv
suggest
lf
improv
specif
tcell
respons
determin
increas
product
potenti
rhlf
reduc
tuberculosi
tissu
damag
pulmonari
histopatholog
also
demonstr
ulterior
studi
group
show
rhlf
produc
yeast
pichia
pastori
express
system
glycosyl
pattern
similar
natur
human
neutrophil
counterpart
contrast
nonglycosyl
rhlf
abl
improv
efficaci
bcg
vaccin
protect
challeng
tuberculosi
aerosol
manifest
primarili
signific
reduct
associ
pulmonari
patholog
case
mycobacteri
load
lung
spleen
significantli
reduc
bcgrhlf
group
compar
control
treat
bcg
alon
rather
protect
associ
chang
patholog
manifest
lung
diseas
probabl
due
notabl
immunomodulatori
function
granulocyt
lf
use
studi
compar
lf
form
secret
microbicid
recent
rhlf
express
chines
hamster
ovari
cho
cell
also
use
mixtur
bcg
vaccin
show
slight
decreas
time
lung
patholog
aerosol
challeng
tuberculosi
correl
initi
increas
secret
inflammatori
cytokin
follow
posterior
decreas
efficaci
blf
enhanc
bcg
vaccin
action
recent
analyz
use
amen
rout
administr
studi
mice
receiv
drink
water
contain
blf
day
postinfect
lower
coloni
form
unit
cfu
lower
inflamm
lung
increas
number
produc
cell
produc
lymphocyt
compar
anim
vaccin
bcg
alon
noteworthi
blf
affect
vitro
replic
tuberculosi
instead
enhanc
kill
bacteria
macrophag
nitric
oxid
depend
way
studi
use
model
pulmonari
infect
tuberculosi
suggest
lf
promot
certain
upregul
proinflammatori
respons
downregul
overal
tissu
immunopatholog
role
lf
inflamm
pulmonari
infect
less
address
homeostat
effect
blf
inflamm
report
vitro
cultur
cystic
fibrosi
cf
bronchial
cell
infect
burkholderia
cenocepacia
gramneg
opportunist
bacterium
recurr
infect
patient
cf
form
biofilm
usual
highli
resist
current
avail
broadspectrum
antibiot
thu
even
though
addit
blf
reduc
rate
bacteri
invas
decreas
releas
proinflammatori
augment
secret
antiinflammatori
suggest
role
blf
protect
cf
bronchial
infect
cell
inflammationassoci
damag
noteworthi
studi
correl
previou
one
address
sputum
sampl
patient
cf
show
invers
associ
level
lf
secret
inflamm
burden
anoth
studi
show
decreas
lf
level
patient
cf
due
cleavag
increas
cathepsin
activ
pseudomona
aeruginosaposit
sputum
sampl
anoth
biofilmform
opportunist
pathogen
patient
similar
result
lf
tf
undergo
proteolysi
previous
report
bronchioalveolar
lavag
p
aeruginosa
infect
cf
patient
result
suggest
proteolyt
cleavag
lf
patient
cf
contribut
b
cenocepacia
p
aeruginosaassoci
lung
damag
infectionassoci
lung
damag
improv
exogen
therapeut
administr
lf
due
potent
immunomodulatori
properti
similar
protect
effect
blf
found
murin
model
lung
injuri
induc
intraperiton
administ
lp
studi
intraperiton
inject
blf
mgmous
h
prophylact
effect
h
therapeut
effect
lp
challeng
associ
signific
reduct
total
number
leukocyt
bronchioalveolar
lavag
sampl
increas
decreas
concentr
myeloperoxidas
activ
chang
parallel
attenu
lung
edema
inflammatori
infiltr
suggest
protect
role
blf
avoid
damag
caus
lpsinduc
acut
inflammatori
respons
howev
protect
role
lf
base
regul
inflamm
observ
case
rt
infect
sever
viral
infect
model
immunomodulatori
effect
lf
document
thu
although
lf
vitro
antivir
activ
respiratori
syncyti
viru
rsv
well
immunomodulatori
effect
reduc
releas
cell
infect
rsv
oral
intraperiton
administr
differ
dose
mganimalday
blf
mice
h
h
postrsv
infect
effect
viral
load
pulmonari
airflow
resist
obstruct
degre
type
pulmonari
inflamm
serum
cellular
respons
evalu
day
postrsv
infect
similar
result
observ
studi
carri
mice
treat
intranas
rout
blf
day
evalu
day
postrsv
infect
anoth
exampl
mous
model
influenza
infect
daili
oral
administr
mg
blf
h
infect
effect
viral
load
concentr
cytokin
evalu
six
day
postinfect
compar
untreat
infect
mice
reason
lack
blf
protect
effect
viral
infect
mice
model
unknown
possibl
explan
could
relat
time
dose
rout
blf
administr
contrast
oral
blf
curcumin
supplement
children
recurr
viral
rt
infect
result
immun
modul
modifi
lymphocyt
popul
cytokin
respons
reduc
rate
infect
recent
studi
aim
determin
effect
three
month
supplement
blffortifi
formula
respiratori
tract
infect
diarrhea
chines
wean
infant
month
age
show
similar
result
reduct
incid
rate
respiratoryrel
ill
compar
placebo
group
moreov
studi
patient
chronic
rhinosinus
establish
associ
genet
defici
lf
synthesi
upper
rt
increas
suscept
certain
individu
bacteri
colon
biofilm
develop
recalcitr
sinu
diseas
new
knowledg
lf
immunomodul
pave
way
gener
design
celldepend
vaccin
incorpor
natur
occur
granulocyt
compon
may
use
infecti
diseas
reduc
immunemedi
tissu
damag
role
blf
inflammatori
respons
associ
infect
describ
mucos
site
mammari
gland
cow
suffer
staphylococc
mastiti
assess
mammari
gland
secret
show
sick
cow
intramammari
infus
blf
decreas
number
staphylococci
increas
level
wherea
healthi
anim
blf
infus
increas
number
pmn
leukocyt
express
integrin
complex
act
receptor
complement
fragment
accord
find
upmodulatori
effect
blf
proinflammatori
compon
innat
immun
may
underli
therapeut
action
toward
mastiti
fact
altern
approach
also
test
decreas
deleteri
effect
inflamm
tissu
integr
combin
blf
antibiot
found
effect
control
staphylococc
mastiti
attenu
mrna
express
via
inhibit
activ
thu
approach
may
contribut
decreas
effect
inflamm
tissu
damag
also
reduc
antibiot
dosag
erad
staphylococc
infect
multiresist
strain
inflammatori
respons
staphylococc
mastiti
seem
correl
elicit
peptid
deriv
blfelastas
proteolysi
display
low
concanavalin
low
ironbind
affin
well
antibacteri
properti
induc
express
proinflammatori
cytokin
lead
neutrophil
infiltr
like
staphylococc
mastiti
elicit
low
cona
affin
lfpeptid
deriv
parotid
saliva
correl
sever
symptom
periodont
patient
oral
caviti
modulatori
action
blf
infectionassoci
inflammatori
respons
document
mice
infect
candida
albican
experiment
set
oral
candidiasi
immunosuppress
mice
show
oral
administr
blf
display
therapeut
effect
inhibit
suppress
effect
infect
inflammatori
paramet
innat
respons
circul
pmn
neutrophil
cervic
lymphnod
cell
moreov
gener
found
increas
cervic
lymphnod
cultur
prime
heatkil
c
albican
blftreat
mice
accord
vitro
assay
test
full
length
blf
blfderiv
peptid
therapeut
effect
parent
blf
reli
ntermin
portion
associ
abil
upmodul
kill
action
pmn
neutrophil
increas
superoxid
gener
protein
kinas
c
mapk
activ
express
find
suggest
murin
model
candidiasi
upmodulatori
effect
blf
paramet
inflamm
provid
protect
c
albican
infect
data
vivo
vitro
assay
support
role
blf
hlf
downmodul
inflammatori
respons
extraintestin
infect
hepat
amoebiasi
listeriosi
urinari
tract
infect
legionellosi
staphylococc
septicemia
experiment
amoeb
liver
abscess
hamster
blf
treatment
gavag
protect
action
hepat
lesion
e
histolytica
favor
normal
liver
function
mind
intrins
antiinflammatori
therapeut
action
well
low
toxic
use
blf
adjunct
convent
drug
metronidazol
may
contribut
decreas
drug
dosag
treatment
amoebiasi
even
decreas
drug
resist
parasit
vitro
experi
listeria
monocytogen
infect
prime
thp
cell
cultur
indic
blf
display
protect
action
cell
death
necrosi
wherea
bovin
lfcin
b
divert
death
cell
necrosi
apoptosi
find
indic
protect
role
blf
lfcin
b
reduc
inflammatori
respons
associ
necrosi
caus
intracellular
infect
pathogen
bacteria
macrophag
favor
antiinflammatori
condit
cell
death
apoptosi
cell
data
studi
infect
l
monocytogen
mice
indic
treatment
hlf
display
signific
effect
one
main
organ
target
pathogen
regard
bacteri
colon
necrosi
mrna
express
proinflammatori
cytokin
although
major
experiment
data
lf
properti
obtain
blf
experiment
studi
indic
hlf
display
even
potent
antibacteri
antiinflammatori
action
murin
model
infect
urinari
bladder
uropathogen
e
coli
strain
show
peror
administ
hlf
decreas
bacteri
load
kidney
urinari
bladder
well
inflammatori
respons
evidenc
reduc
level
urin
h
postinfect
plasma
h
postinfect
thu
hlf
administ
peror
rout
provid
therapeut
action
infect
inflamm
remot
site
urinari
tract
vitro
assay
legionella
pneumophila
infect
cultur
monocyt
healthi
volunt
indic
unlik
holohlf
promot
bacteri
grow
apohlf
inhibit
intracellular
multipl
pathogen
inactiv
activ
monocyt
find
suggest
synergi
antibacteri
effect
ironfre
human
lactoferrin
stimul
killer
effect
proinflammatori
cytokin
infect
cell
lead
condit
control
bacteri
multipl
insid
cell
model
aureu
infect
hlftransgen
mice
show
pivot
role
hlf
elicit
profil
cytokin
determin
resolut
system
infect
polar
immun
respons
profil
hlftransgen
mice
evidenc
upmodul
level
downmodul
cytokin
cultur
supernat
spleen
cell
summari
studi
mention
show
lf
deriv
peptid
display
bimod
effect
provid
condit
downregul
inflamm
lead
resolut
extraintestin
infect
biotechnolog
develop
formul
lf
nanoparticl
potenti
clinic
use
addit
lfhydrolys
nativ
lf
alon
combin
probiot
may
applic
control
infect
inflamm
evid
basic
studi
anim
experiment
prophylact
therapeut
activ
lf
antimicrobi
modulatori
agent
inflammatori
respons
promot
glycoprotein
innat
immun
system
focu
interest
biotechnolog
develop
nanoparticlebas
formul
potenti
clinic
use
addit
lfhydrolys
nativ
lf
alon
combin
antibiot
probiot
may
potenti
applic
control
neonat
infect
inflamm
studi
necessari
support
gener
practic
applic
lf
mainli
control
inflamm
associ
infect
